Iterum tests pub­lic mar­ket's ap­petite for an­ti-in­fec­tives in $92M IPO

A year ago, the ex-Du­ra­ta ex­ecs at Iterum Ther­a­peu­tics un­veiled a $65 mil­lion B round and a Phase III game plan for the an­tibi­ot­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.